- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT01888185
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
2 stycznia 2020 zaktualizowane przez: Xuemei Huang, MD, PhD, Milton S. Hershey Medical Center
Multimodal MRI Markers of Nigrostriatal Pathology in Parkinson's Disease
This study is designed to determine if magnetic resonance imaging (MRI) measures can be used to diagnose and monitor the progression of Parkinson's disease (PD) while distinguishing between PD and parkinsonisms [conditions that are PD look-a-like diseases such as progressive supranuclear palsy (PSP) or multiple system atrophy (MSA)] when combined with changes in certain proteins in body fluids that are related to iron (Fe).
Przegląd badań
Status
Zakończony
Szczegółowy opis
The lack of in vivo biomarker(s) reflecting Parkinson's disease (PD)-related cell loss and associated pathoetiological/physiological processes in nigrostriatal structures has hindered discovery research and limited the ability to evaluate disease-modifying therapies.
Recent research has generated excitement for using DTI and R2* MRI measures as biomarker(s) for PD-related pathology in nigrostriatal pathways, but they fall short by the lack of understanding of their clinical implications and biological/pathological underpinnings.
Working closely with the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease Biomarkers Program (PDBP), the proposed work will investigate multimodal MRI techniques in combination with fluid-based iron (Fe) protein profiles to serve as in vivo markers for PD-related nigrostriatal pathology that can be used as biomarkers for diagnosing PD, following its progression, and gaining mechanistic understanding of PD pathoetiology and pathophysiology.
Typ studiów
Obserwacyjny
Zapisy (Rzeczywisty)
290
Kontakty i lokalizacje
Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.
Lokalizacje studiów
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stany Zjednoczone, 17033
- Penn State Milton S. Hershey Medical Center and College of Medicine
-
-
Kryteria uczestnictwa
Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.
Kryteria kwalifikacji
Wiek uprawniający do nauki
21 lat do 90 lat (Dorosły, Starszy dorosły)
Akceptuje zdrowych ochotników
Tak
Płeć kwalifikująca się do nauki
Wszystko
Metoda próbkowania
Próbka bez prawdopodobieństwa
Badana populacja
Clinical patients and community volunteers
Opis
Inclusion Criteria:
PD Subjects:
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- MMSE score of 15 or greater unless a legal representative is present.
- Idiopathic PD according to published criteria.
- History of adequate response to dopaminergic therapy.
- History of asymmetrical symptom onset
MSA Subjects:
- Older than 30 yrs.
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- MMSE score of 15 or greater unless a legal representative is present.
- MSA according to published criteria.
- History of autonomic & urinary dysfunction and/or severe cerebellar ataxia.
PSP Subjects:
- Older than 40 yrs.
- Able and willing to sign the consent form at time of initial enrollment or if the subject is decisionally impaired and has a legal representative that is able and willing to sign a consent form at the time of the enrollment. If the subject becomes decisionally impaired during the course of the study, their legal representative may sign an addendum to consent for continued participation.
- PSP according to published criteria.
- Vertical gaze palsy and/or slow vertical gaze/postural instability during first year of diagnosis.
- MMSE score of 15 or greater unless a legal representative is present
Controls:
- Older than 21 yrs.
- Able and willing to sign the consent form.
- MMSE greater than 24.
Exclusion Criteria:
PD Subjects:
- Unable or does not have a legal representative/unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-PD-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
MSA Subjects:
- Unable or does not have a legal representative /unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-MSA-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
PSP Subjects:
- Unable or does not have a legal representative /unwilling to provide consent.
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable, non-PSP-related medical conditions.
- MMSE score less than 15 unless a legal representative is present
- Use of anticoagulant medications.
- Signs of dementia.
Controls:
- Unable/unwilling to provide consent.
- Evidence of severe memory impairment or signs of dementia (MMSE < 24).
- Any condition that precludes a routine MRI (e.g., claustrophobia, pacemaker, severe scoliosis, etc.).
- History of cerebrovascular diseases or other neurological disorders.
- Major medical problems such as renal or liver failure.
- Unstable medical conditions.
- Use of anticoagulant medications.
- Signs of dementia.
Plan studiów
Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
---|
Parkinson's Disease (PD)
Patients with a clinical diagnosis of PD (in various stages)
|
Progressive supranuclear palsy (PSP)
Patients with a clinical diagnosis of PSP (in various stages)
|
Multiple system atrophy (MSA)
Patients with a clinical diagnosis of MSA (in various stages)
|
Controls
Age and gender-matched adults free from neurological disease
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Differential roles of fractional anisotropy (FA) and R2* in PD detection and progression
Ramy czasowe: Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
Substantia Nigra (SN) FA and R2* values in PD subjects will be compared with control subjects and correlated with clinical and behavioral measures.
|
Change in roles of FA and R2* assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
---|---|---|
Nigrostriatal diffusion tensor imaging (DTI) and R2* differentiate PD from parkinsonian syndromes
Ramy czasowe: Assessed at baseline visit.
|
DTI and R2* measures in both SN and striatal structures in PD, PSP, MSA and control subjects will be compared to assess sensitivity and specificity of individual and combined MRI measures in diagnosing PD.
|
Assessed at baseline visit.
|
Iron(Fe)-related proteins in body fluids as biomarkers of PD
Ramy czasowe: Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
The protein profile in blood, urine, and cerebral spinal fluid (CSF), and their relationships to clinical and MRI measure will be interrogated with the focus being on Fe-related proteins such as hepcidin, ferritin, and transferrin.
|
Change assessed between baseline and 18 months. Change assessed between baseline and 36 months. Change assessed between 18 and 36 months.
|
MRI and postmortem pathological correlation
Ramy czasowe: From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease
|
Postmortem brain analysis on patients who succumb to their disease during the study will be performed in order to inform the relationship of the biomarkers to clinical diagnosis (PD, PSP, MSA) and clinical milestones as well as to inform the pathological underpinnings of the R2* and DTI measures.
In addition to standard postmortem diagnostic tests (alpha-synuclein, beta-amyloid, tau, and ubiquitin), total Fe staining, ferritin, hepcidin, tyrosine hydroxylase positive neurons, myelin and glial derived growth factors (glial cell markers) will be assessed in nigrostriatal structures in order to correlate these levels with MRI measures.
|
From baseline until date of death from any cause within 5 years for patient participants who succumb to their disease
|
Współpracownicy i badacze
Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.
Sponsor
Publikacje i pomocne linki
Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.
Daty zapisu na studia
Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.
Główne daty studiów
Rozpoczęcie studiów
1 grudnia 2012
Zakończenie podstawowe (Rzeczywisty)
1 grudnia 2019
Ukończenie studiów (Rzeczywisty)
31 grudnia 2019
Daty rejestracji na studia
Pierwszy przesłany
17 stycznia 2013
Pierwszy przesłany, który spełnia kryteria kontroli jakości
25 czerwca 2013
Pierwszy wysłany (Oszacować)
27 czerwca 2013
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
3 stycznia 2020
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
2 stycznia 2020
Ostatnia weryfikacja
1 stycznia 2020
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu krążenia
- Choroby naczyniowe
- Choroby mózgu
- Choroby ośrodkowego układu nerwowego
- Choroby Układu Nerwowego
- Choroby oczu
- Objawy neurologiczne
- Choroby jąder podstawy
- Zaburzenia ruchowe
- Synukleinopatie
- Choroby neurodegeneracyjne
- Tauopatie
- Choroby nerwów czaszkowych
- Choroby autonomicznego układu nerwowego
- Zaburzenia motoryki oka
- Paraliż
- Pierwotne dysautonomie
- Niedociśnienie
- Oftalmoplegia
- Choroba Parkinsona
- Atrofia wielu systemów
- Syndrom Shy-Dragera
- Zaburzenia Parkinsona
- Porażenie nadjądrowe, postępujące
Inne numery identyfikacyjne badania
- MSHersheyMC-40726
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .